| Literature DB >> 31616316 |
Wesam Mulla1,2, Barak Hajaj3, Sigal Elyagon1,2, Michal Mor1, Roni Gillis1,2, Michael Murninkas1,2, Hadar Klapper-Goldstein1,2, Inbar Plaschkes4, Vered Chalifa-Caspi4, Sharon Etzion2, Yoram Etzion1,2.
Abstract
AIM: The self-perpetuating nature of atrial fibrillation (AF) has been a subject of intense research in large mammalian models exposed to rapid atrial pacing (RAP). Recently, rodents are increasingly used to gain insight into the pathophysiology of AF. However, little is known regarding the effects of RAP on the atria of rats and mice. Using an implantable device for electrophysiological studies in rodents, we examined on a daily basis, the effects of continuous RAP on the developed AF substrate of unanesthetized rats and mice. METHODS ANDEntities:
Keywords: atrial fibrillation substrate; atrial remodeling; atrial tachycardia; atrial tachypacing; rodent electrophysiology
Year: 2019 PMID: 31616316 PMCID: PMC6763969 DOI: 10.3389/fphys.2019.01218
Source DB: PubMed Journal: Front Physiol ISSN: 1664-042X Impact factor: 4.566
FIGURE 1AF substrate analysis in unanesthetized rodents. (A) Schematic presentation of the experimental setup. MBHE was implanted on the RA for atrial pacing. One pole of the atrial electrode was also utilized to acquire high resolution recordings of the atrial signal (Atrial-Unipolar). (B) Photographs of an implanted rat and an implanted mouse freely moving in the EP cage during the RAP protocol. (C) Example of an AF episode triggered by burst pacing. This episode of 82 s was recorded from a rat that was exposed to RAP for 7 consecutive days (see Figure 2 for details). Left: Baseline ECG and atrial-unipolar recordings. Middle: Standard burst pacing protocol (20 s, 100 Hz, double threshold). Right: Post-burst recordings of an AF episode and its conversion to sinus rhythm. In each condition, 10 consecutive bursts were applied. AF substrate was evaluated in regard to the % of positive episodes (>1 s) and the total AF duration.
FIGURE 2Increased AF substrate in rats exposed to RAP. (A) Analysis of AF induction. 3D plots of daily evaluation in five RAP rats (left) and six Sham rats (right). In both plots each color represents a different rat. For the RAP animals evaluation was continued until capture was lost or was too high to keep with the RAP. For the Shams, evaluation was maintained for 6–8 days. Note absence of AF induction in the majority of rats at baseline as well as following 1 day of RAP. Also note increased AF substrate following 2 days of RAP. (B) Analysis of Total AF duration. 3D representation as in (A) above. (C,D) Comparison of the AF substrate parameters before and after 2 days in the RAP vs. Sham rats. Note the strong tendency of increase in AF induction and AF duration following 2 days in the RAP group. Also note increased AF duration following 2 days in the RAP group vs. the Sham group.
FIGURE 4Paradigm for evaluation of transcriptional effects of RAP on left atrial tissue of rats. (A,B) Schematic diagrams of microarray study design and basic outcome. (C,D) RT-qPCR for eight genes of interest indicating data reliability.
FIGURE 3Absence of AF substrate augmentation in mice exposed to RAP. (A,B) Analysis of AF induction and AF duration in seven mice in which RAP could be maintained for up to 7 consecutive days. 3D plots of daily AF evaluation as in Figure 2. Note that only one animal demonstrated AF episodes and no clear effect of the RAP could be detected. (C,D) Summary analysis comparing the AF substrate before and after 48 h of continuous RAP at CL = 50 ms. Note absence of AF substrate augmentation following RAP in mice.
Enrichment analysis of LA gene expression in response to RAP.
| 1 | Development_TGF-beta-dependent induction of EMT via MAPK | 2.112E-03 | 4/47 |
| 2 | Immune response_Lectin induced complement pathway | 2.465E-03 | 4/49 |
| 3 | Cytoskeleton remodeling_Neurofilaments | 2.936E-03 | 3/25 |
| 4 | Immune response_Classical complement pathway | 3.067E-03 | 4/52 |
| 5 | Immune response_IL-6 signaling pathway | 4.510E-03 | 3/29 |
| 6 | Mucin expression in CF via IL-6, IL-17 signaling pathways | 7.083E-03 | 3/34 |
| 7 | Immune response_Oncostatin M signaling via MAPK in mouse cells | 7.682E-03 | 3/35 |
| 8 | Development_TGF-beta-dependent induction of EMT via SMADs | 7.682E-03 | 3/35 |
| Immune response_Oncostatin M signaling via MAPK in human cells | 8.968E-03 | 3/37 | |
| 10 | Immune response_Human NKG2D signaling | 9.656E-03 | 3/38 |
| 1 | Development_Skeletal muscle development | 1.561E-03 | 8/144 |
| 2 | Muscle contraction | 4.866E-03 | 8/173 |
| 3 | Inflammation_IL-6 signaling | 9.594E-03 | 6/119 |
| 4 | Apoptosis_Apoptotic nucleus | 1.076E-02 | 7/159 |
| 5 | Development_Regulation of angiogenesis | 2.060E-02 | 8/223 |
| 6 | Inflammation_Complement system | 2.519E-02 | 4/73 |
| 7 | Inflammation_Amphoterin signaling | 3.426E-02 | 5/118 |
| 8 | Cytoskeleton_Intermediate filaments | 3.512E-02 | 4/81 |
Enrichment analysis: Rat RAP vs. Human AF.
| 1 | Glycolysis and gluconeogenesis p. 1 | 2.231E-03 | 5/46 |
| 2 | Glycolysis and gluconeogenesis (short map) | 4.544E-03 | 8/66 |
| 3 | Development_Ligand-dependent activation of the ESR1/AP-1 pathway | 2.161E-02 | 6/14 |
| 4 | Regulation of lipid metabolism_Regulation of acetyl-CoA carboxylase 2 activity in muscle | 2.922E-02 | 3/19 |
| 5 | Apoptosis and survival_NO signaling in apoptosis | 3.527E-02 | 4/23 |
| 6 | Transcription_Transcription regulation of aminoacid metabolism | 3.828E-02 | 8/25 |
| 7 | Muscle contraction_nNOS Signaling in Skeletal Muscle | 4.279E-02 | 5/28 |
| 8 | Histamine metabolism | 4.428E-02 | 5/29 |
| 9 | Transcription_Ligand-dependent activation of the ESR1/SP pathway | 4.578E-02 | 4/30 |
| 10 | Glycolysis and gluconeogenesis p. 2 | 4.876E-02 | 3/32 |
Rat ATR vs. Human AF; commonly regulated genes.
| Up | AARSD1 | Alanyl-tRNA synthetase domain containing 1 | Alanyl-tRNA aminoacylation |
| ADSL | Adenylosuccinate lyase | AMP biosynthetic process | |
| ASPN | Asporin | Negative regulation of transforming growth factor | |
| COQ6 | Coenzyme Q6 homolog ( | Ubiquinone biosynthesis process | |
| FASTKD5 | FAST kinase domains 5 | Mitochondrion | |
| GAPDH | Glyceraldehyde-3-phosphate dehydrogenase | Glycolysis_and_ Gluconeogenesis | |
| KCNJ2 | Potassium inwardly-rectifying channel, subfamily J, member 2 | Ion transport | |
| MAFK | V-maf musculoaponeurotic fibrosarcoma oncogene homolog K (avian | Transcription, DNA-dependent | |
| PFKP | Phosphofructokinase, platelet | Glycolysis and Gluconeogenesis | |
| PPID | Peptidylprolyl isomerase D (cyclophilin D) | Protein folding | |
| Down | Tcfe2a | Transcription factor E2a | Muscle cell differentiation/positive regulation of B cell proliferation |
| FLRT2 | Fibronectin leucine rich transmembrane protein 2 | Cell adhesion | |
| FOXP1 | Forkhead box P1 | Specific transcriptional repressor activity | |
| OS9 | Osteosarcoma amplified 9, endoplasmic reticulum lectin | Response to endoplasmic reticulum stress | |
| PON2 | Paraoxonase 2 | Response to oxidative stress | |
| TMEM108 | Transmembrane protein 108 | ? | |
| CRTC3 | CREB regulated transcription coactivator 3 | Positive regulation of CREB transcription factor | |
| TRIM8 | Tripartite motif-containing 8 | Protein ubiquitination | |
| ZMIZ1 | Zinc finger, MIZ-type containing 1 | Regulation of transcription, DNA-dependent |
FIGURE 5Analysis of four Micro RNAs known to be involved in AF-related remodeling. Note significant downregulation of MIR-101, and MIR-26A as well as a non-significant tendency of reduction in MIR-1. MIR-328 was unaffected by RAP (n = 3 for both RAP and control pacing, Mahan–Whitney test).